Side-by-side comparisons
Compare GLP-1 drugs and telehealth providers
Independent head-to-head analysis. Each comparison covers weight-loss data, cost, side effects, and which type of patient each option fits best.
Drug-vs-drug comparisons
Mounjaro vs Ozempic: Which Is Better in 2026?
Mounjaro (tirzepatide) typically delivers more weight loss than Ozempic (semaglutide) in head-to-head clinical trial comparisons — averaging 15–22% body-weight reduction versus 14.9% — but it costs more out-of-pocket and is FDA-approved only for type 2 diabetes, not weight loss. For chronic weight management, the FDA-approved equivalents are Zepbound (same molecule as Mounjaro) and Wegovy (same molecule as Ozempic).
Read comparison
Semaglutide vs Tirzepatide: 2026 Comparison
Tirzepatide (the active ingredient in Mounjaro and Zepbound) delivers more weight loss on average than semaglutide (the active ingredient in Ozempic and Wegovy) — roughly 5 percentage points more body-weight reduction in clinical trials. Semaglutide costs less, has a longer real-world track record, and is the more common starting molecule. The right choice depends on goals, tolerance, and budget.
Read comparison
Wegovy vs Ozempic: What Is Actually Different?
Wegovy and Ozempic contain the same active ingredient — semaglutide. The differences are dose (Wegovy reaches higher therapeutic doses), FDA approval (Wegovy for chronic weight management, Ozempic for type 2 diabetes), and price (Wegovy lists slightly higher). Insurance treats them very differently because of the indication on the prescription.
Read comparison
Zepbound vs Wegovy: 2026 Head-to-Head
Zepbound (tirzepatide) generally produces more weight loss than Wegovy (semaglutide) — clinical trials show 15–22% versus 14.9% body-weight reduction. Zepbound is more expensive at list price but has aggressive 2026 self-pay programs. Both are FDA-approved specifically for chronic weight management, which matters for insurance coverage.
Read comparison